Showing 1 posts of 1 posts found.

Allogene Therapeutics shares updated ALLO-501/501A phase 1 data in large B-cell lymphoma at ASCO annual meeting

June 5, 2023
Research and Development Allogene, LBCL, Oncology, lymphoma, oncology

Allogene Therapeutics has shared updated data from the phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A in patients with relapsed/refractory (r/r) large …

Latest content